Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-268113
Filing Date
2025-11-06
Accepted
2025-11-06 07:48:37
Documents
94
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q lnth-20250930.htm   iXBRL 10-Q 3601579
2 EX-10.1 lnth-ex10_1.htm EX-10.1 2145235
3 EX-31.1 lnth-ex31_1.htm EX-31.1 19180
4 EX-31.2 lnth-ex31_2.htm EX-31.2 19463
5 EX-32.1 lnth-ex32_1.htm EX-32.1 20010
6 GRAPHIC img148029422_0.jpg GRAPHIC 3517
  Complete submission text file 0001193125-25-268113.txt   16288998

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lnth-20250930.xsd EX-101.SCH 1518982
97 EXTRACTED XBRL INSTANCE DOCUMENT lnth-20250930_htm.xml XML 2880551
Mailing Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862
Business Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 978 671-8001
Lantheus Holdings, Inc. (Filer) CIK: 0001521036 (see all company filings)

EIN.: 352318913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36569 | Film No.: 251456224
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)